{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:33:20Z","timestamp":1760524400198,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II\/III trial designed to test whether consolidation with obinutuzumab is safe and eradicates minimal residual disease (MRD) and, subsequently, whether this leads to prolonged progression\u2010free survival (PFS) in patients with CLL who have recently responded to chemo\u2010immunotherapy. Patients with a response 3\u201324\u2009months after chemotherapy were assessed for MRD. MRD\u2010positive patients were randomised to receive consolidation therapy with obinutuzumab or no consolidation. The trial closed after the phase II part due to slow recruitment. In all, 48 patients enrolled of whom 19 were MRD negative and were monitored. Of the 29 MRD\u2010positive patients, 14 were randomised to receive consolidation and 15 to no consolidation. At 6\u2009months after randomisation, 10 and 13 consolidated patients achieved MRD negativity by flow cytometry (sensitivity 10<jats:sup>\u22124<\/jats:sup>) in bone marrow and peripheral blood respectively. PFS was significantly better in consolidated patients compared to non\u2010consolidated patients (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.001). No difference was observed in PFS, overall survival or duration of MRD negativity when comparing the 10 MRD\u2010negative patients after consolidation with the 19 MRD\u2010negative patients in the monitoring group. Common adverse events in the consolidation arm were thrombocytopenia, infection, and cough. Only 1% of events were infusion\u2010related reactions. This observation provides further evidence that consolidation to achieve MRD negativity improves outcomes in CLL and that obinutuzumab is well tolerated in patients with low levels of disease.<\/jats:p>","DOI":"10.1111\/bjh.18427","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:04:34Z","timestamp":1661511874000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Obinutuzumab as consolidation after chemo\u2010immunotherapy: Results of the <scp>UK National Cancer Research Institute<\/scp> phase <scp>II<\/scp>\/<scp>III GALACTIC<\/scp> trial"],"prefix":"10.1111","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"first","affiliation":[{"name":"St James's Institute of Oncology, St James's University Hospital  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Emmerson","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie B.","family":"Oughton","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-9783","authenticated-orcid":false,"given":"Dena","family":"Howard","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Phillips","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Neilson","sequence":"additional","affiliation":[{"name":"Russell Hall Hospital  Dudley UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Pemberton","sequence":"additional","affiliation":[{"name":"Worcestershire Royal Hospital  Worcestershire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[{"name":"Birmingham Heartlands Hospital  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Leicester Royal Infirmary  Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Rawstron","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, St James's Institute of Oncology, St James's University Hospital  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-4403","authenticated-orcid":false,"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"St James's Institute of Oncology, St James's University Hospital  Leeds UK"},{"name":"Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_8_3_1","unstructured":"CANCER RESEARCH UK.Chronic lymphocytic leukaemia (cll) incidence statistics2016."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583765"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714162"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.65"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.96"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta21280"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14342"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07394.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.781169"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000107"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.216"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7978"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30235-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0260-2"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.07.003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.133421"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586610"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000303"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-181"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"4450824","DOI":"10.1155\/2022\/4450824","article-title":"Ibrutinib plus Obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion\u2010related reactions and with sustained remissions after ibrutinib discontinuation: a single\u2010arm, open\u2010label, phase 1b\/2 clinical trial NCT0231576","volume":"2022","author":"Castro JE","year":"2022","journal-title":"Adv Hematol"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18427","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T20:30:18Z","timestamp":1692563418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/bjh.18427"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18427","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"2022-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}